compare to NEU, Rett Syndrome approval, share price close to doubled in around a week.
I think the moral of the story is, no one knows the true outcome until it does happen.
but as we see with NEU and others, and as you mention really the true test is going to be sales data. There might be some good catalysts like sales agreements etc between hopeful FDA approval and sales data but that’s really when the rubber hits the road for investors.
compare to NEU, Rett Syndrome approval, share price close to...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $624.4M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.0¢ | 33.0¢ | $2.271M | 6.715M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 83805 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 112605 | 3 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |